Perhaps this has already happened to you. You are seeing a school-aged girl for general health maintenance, and her parents say, “We had our child tested by 23andMe and found that she is at risk for developing HFE-related hemochromatosis. What should we do?” Fortunately, in women, this disorder rarely becomes symptomatic or requires medical intervention before menopause, so you can reassure them. You may suggest that they talk with their physicians about their own risk. You may also wonder idly whether the child will be assessed for hemochromatosis in mid to late adulthood when detection would more appropriate, but you decide that medical science will be even better then.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Clayton EW. Be Ready to Talk With Parents About Direct-to-Consumer Genetic Testing. JAMA Pediatr. 2020;174(2):117–118. doi:10.1001/jamapediatrics.2019.5006
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: